Wexford Capital LP Fennec Pharmaceuticals Inc. Call Options Transaction History
Wexford Capital LP
- $477 Million
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding FENC
# of Institutions
69Shares Held
14.4MCall Options Held
53.2KPut Options Held
83.9K-
Southpoint Capital Advisors LP New York, NY4.08MShares$24.9 Million1.02% of portfolio
-
Sonic Gp LLC Honolulu, HI2.41MShares$14.7 Million35.34% of portfolio
-
Dg Capital Management, LLC New York, NY1.51MShares$9.24 Million10.39% of portfolio
-
Solas Capital Management, LLC Darien, CT1.11MShares$6.78 Million8.43% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.01MShares$6.19 Million0.0% of portfolio
About FENNEC PHARMACEUTICALS INC.
- Ticker FENC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,067,300
- Market Cap $159M
- Description
- Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec...